Why your eyes are telling you something important about your hormones – and the complete evidence-based treatment approach

Dry Eyes During Perimenopause and Menopause: The Ophthalmological Guide

Why your eyes are telling you something important about your hormones – and the complete evidence-based treatment approach

The Symptom That Nobody Connects to Menopause

You feel a gritty, sandy sensation in your eyes that is there when you wake up and worsens through the day. Reading from a screen – which used to be effortless – now causes burning and blurring after 20 minutes. Your eyes water in cold or windy weather, paradoxically, and yet feel constantly dry the rest of the time. You reach for over-the-counter eye drops with increasing frequency, finding temporary relief that lasts less and less time.

The possibility that these symptoms are connected to perimenopause rarely occurs to you. It almost certainly does not occur to the pharmacist who recommended the drops. And in many cases, it does not occur to the GP or gynecologist managing your other menopausal symptoms either.

Dry eye disease (DED) during the menopausal transition is one of the most prevalent and most consistently under-recognized symptoms of this period. Dry eye disease is a multifactorial ocular surface disease that causes symptoms of ocular pain, discomfort, and decreased visual acuity. It significantly affects the quality of life of patients. It is more prevalent in females and specifically in the menopausal and postmenopausal age group. This is believed to be due to changes in the balance of sex hormones.

This article explains the ophthalmological science behind menopausal dry eye, the full spectrum of its clinical presentations, the treatment hierarchy from self-care to prescription, and the critical role of omega-3 fatty acids – which have a more nuanced evidence base than most supplement recommendations suggest.

Part 1: How Sex Hormones Govern Tear Film Health

The Tear Film: More Complex Than You Realize

Before understanding how menopause disrupts tear production, it is essential to understand what healthy tears actually are. The tear film is not simply water – it is a precisely structured three-layer system:

The outer lipid (oil) layer – secreted by the meibomian glands, 25–30 oil-producing glands located in the upper and lower eyelids. This layer prevents tear evaporation, provides optical clarity, and prevents contamination of the tear film. It is the layer most critically impacted by menopause.

The middle aqueous (watery) layer – secreted by the lacrimal glands, providing oxygen and nutrients to the corneal surface, washing away debris, and comprising the largest volume of the tear film.

The inner mucin layer – produced by goblet cells in the conjunctiva, anchors the tear film to the ocular surface, prevents dehydration of the corneal epithelium, and enables the even spreading of tears with each blink.

All three layers are regulated, to varying degrees, by sex hormones. When those hormones change – as they do, dramatically, during perimenopause and menopause – the stability and composition of the entire tear film is disrupted.

Androgens: The Most Important Hormonal Driver of Tear Health

The central insight of modern dry eye ophthalmology – one that overturns decades of assumption – is that androgens, not estrogen, are the primary hormonal drivers of meibomian gland health and tear film stability.

Sex hormone receptors – specifically androgen and estrogen receptors – are present on the meibomian glands, which are the sebaceous glands on the eyelids responsible for producing the oil component of tears that prevents evaporation. Androgen binding results in synthesis and secretion of lipids from these glands.

The major cause of dry eye disease is meibomian gland dysfunction. Meibomian glands, which are large sebaceous glands situated in the eyelids, secrete an oil and protein mixture that stabilizes and prevents the evaporation of the tear film, and play an essential role in the health and well-being of the ocular surface. Conversely, meibomian gland dysfunction destabilizes the tear film, increases its evaporation, and is a key trigger for the induction of dry eye disease.

During perimenopause and menopause, androgen levels – which women produce in smaller quantities than men but which are physiologically essential – fall significantly. As androgen activity decreases, the meibomian glands receive less hormonal stimulation, producing less meibum (the oily secretion) of lower quality. The lipid layer of the tear film thins. Tear evaporation accelerates. The result is evaporative dry eye – the most common form of dry eye disease, and the form most specifically associated with the menopausal transition.

The aqueous layer is similarly affected: the middle aqueous (watery) layer is produced by the lacrimal glands, which are also influenced by androgen hormones. As androgen activity decreases, the lacrimal glands may become inflamed and produce fewer tears. Some women experience a combination of reduced tear volume and increased evaporation – a condition called mixed mechanism dry eye.

Estrogen: A More Complicated Picture

The relationship between estrogen and dry eye is counterintuitive and frequently misunderstood – including by clinicians. Estrogens, and chemicals that act as estrogens, may actually promote the development of dry eye disease, while androgens may prevent it.

Estrogens actually cause a decrease in lipid production from meibomian glands. For this reason, increased levels of estradiol are believed to be a risk factor for dry eye disease.

This explains a clinical paradox that has confused both patients and researchers: some perimenopausal women whose estrogen is surging (a common occurrence in early perimenopause) experience dry eye symptoms alongside high estrogen levels. It also explains why estrogen-only HRT carries a higher dry eye risk than combined estrogen-progesterone therapy – the progestogen component partially offsets estrogen’s negative effect on meibomian gland lipid production.

Estrogen receptors are present on the conjunctiva, cornea, and lacrimal glands – and estrogen has documented effects on mucin production and conjunctival health. The relationship is therefore not simply that estrogen is bad for eyes; rather, it is that the hormonal transition produces a disruption of the finely balanced interplay between androgens and estrogens that governs tear film stability.

The Screen and Environment Amplifier

The glands that produce the oil layer of the tears – the meibomian glands – are impacted by the drop in hormones estrogen, progesterone and testosterone that starts as a woman enters perimenopause. This causes less oil volume and lower oil quality in tears. When the oil layer is low, tears evaporate too quickly. Any time that blinking is reduced – such as when looking at screens for an extended period – dry eye symptoms will worsen. Similarly, if the oil layer is compromised, being outside in cold or windy conditions will make the eyes feel dry or cause over-tearing.

The modern work environment – extended screen time, air-conditioned offices, video conferencing – dramatically reduces blink rate (from 15–20 blinks per minute to 5–8 during screen use) and increases tear evaporation. For perimenopausal women whose meibomian gland function is already compromised, these environmental factors convert a moderate hormonal disruption into a clinically significant daily symptom burden.

The Cosmetics Dimension

A 2024 review in The Ophthalmologist by researchers at the University of Cambridge and Sullivan DEWS laboratory added an important and underreported dimension: with the cumulative use of eye makeup and skincare products that contain parabens (such as ethylparaben and methylparaben) or essential oils such as tea tree oil (terpinen-4-ol), the process of perimenopausal dry eye disease can be expedited. Parabens abound in many around-eye creams, eyeliners, eyeshadows, glitter, mascaras, moisturizers, and serums. These compounds may block androgen receptors in meibomian glands, further reducing the already-compromised lipid secretion.

Women who are conscientiously using multiple eye-area skincare and cosmetic products – precisely the women most likely to be attentive to their appearance during a transition that challenges body image – may inadvertently be contributing to the very problem they are trying to conceal.

Part 2: The Clinical Picture – What Menopausal Dry Eye Feels Like

Dry eye disease during menopause presents with a characteristic and recognizable symptom cluster, though individual variation is significant:

Grittiness and foreign body sensation – the most commonly reported symptom. The sensation that something is in the eye – a grain of sand, a particle – that cannot be located or removed.

Burning and stinging – particularly with exposure to dry air, air conditioning, heating systems, smoke, and screens.

Blurring of vision – typically transient, improving with blinking. The blurring is not a refractive error; it is caused by the irregular tear film surface producing optical distortion. If blurring is persistent and not relieved by blinking, ophthalmological assessment is warranted.

Paradoxical tearing – one of the most confusing aspects of dry eye for patients and clinicians alike. Dry, irritated eyes reflexively stimulate the lacrimal gland to produce watery tears (the reflex tearing response). Because these reflex tears are not the stable, oil-containing tears produced under normal conditions, they immediately evaporate rather than lubricating the eye – and the cycle of dryness and reflexive tearing continues. Women who report that their eyes water constantly may actually be experiencing severe dry eye.

Morning dryness and blurry vision on waking – caused by reduced tear production and increased evaporation during sleep, particularly in mouth-breathers or those with incomplete eyelid closure. The eye is at its driest on waking and takes time to stabilize.

Photophobia – light sensitivity, driven by ocular surface inflammation and nerve sensitization that accompanies chronic dry eye disease.

Contact lens intolerance – many women who have comfortably worn contact lenses for years find that contact lens tolerance deteriorates significantly during perimenopause, as reduced tear volume and quality makes lens wear uncomfortable.

Part 3: When to Seek Ophthalmological Assessment

Most mild to moderate dry eye can be initially managed with the measures described below. However, certain presentations require formal ophthalmological evaluation:

Seek assessment from an eye specialist when:

• Symptoms are significantly affecting vision or daily function despite basic self-care measures
• Vision blurring is persistent or worsening
• There is visible redness of the eye that does not settle within days
• Pain in the eye (rather than discomfort or grittiness) – genuine ocular pain has a distinct clinical significance and requires examination to exclude corneal pathology
• Contact lens wear has become impossible or causes persistent irritation
• Any change in the shape of the visual field, sudden new floaters, or flashes of light – these may indicate retinal issues unrelated to dry eye and require urgent ophthalmological assessment
• Dry eye symptoms appear alongside other sicca symptoms (dry mouth, joint pain, vaginal dryness with systemic inflammatory symptoms) – this clinical constellation may indicate Sjögren’s syndrome, an autoimmune condition affecting exocrine glands

An ophthalmologist or optometrist with dry eye expertise will perform specific tests that cannot be assessed from symptom description alone: tear break-up time (TBUT – how long the tear film remains stable between blinks), Schirmer’s test (a measure of aqueous tear production), meibography (infrared imaging of meibomian gland structure to identify dropout and atrophy), corneal staining (using fluorescein or rose bengal dye to identify epithelial damage from dry eye), and tear osmolarity measurement.

These investigations determine whether dry eye is aqueous-deficient (insufficient tear volume), evaporative (insufficient lipid layer from meibomian gland dysfunction), or mixed – and this diagnosis directly guides treatment selection.

Part 4: The Treatment Hierarchy – From Self-Care to Prescription

Step 1: Environmental and Behavioral Modification

These measures cost nothing and have immediate, meaningful benefit:

The 20-20-20 rule for screen use – every 20 minutes, look at something 20 feet away for 20 seconds, and consciously blink fully several times. This interrupts the reduced blink rate of screen use and allows tear film restoration.

Workspace humidity – a desk humidifier in air-conditioned environments measurably reduces tear evaporation rate. Directing air vents away from the face reduces direct evaporation stimulus.

Protective eyewear – wraparound glasses or moisture chamber glasses for outdoor use in windy or cold conditions significantly reduce evaporative loss. This is particularly relevant for women experiencing paradoxical tearing in outdoor environments.

Screen positioning – positioning screens below eye level (rather than at or above) reduces the exposed ocular surface area during screen use, slowing evaporation.

Review eye cosmetics – switching to paraben-free eye area products and avoiding essential oil-containing removers and cleansers around the eyes may reduce the meibomian gland disruption described above.

Step 2: Eyelid Hygiene and Warm Compresses

For women with meibomian gland dysfunction – the primary driver of menopausal dry eye – eyelid hygiene is as important as any drop formulation:

Warm compress therapy – applying a warm, moist cloth or heated eye mask (reusable gel masks that retain heat for 8–10 minutes are most effective) to closed eyelids for 10 minutes daily softens the thickened, solidified meibum that blocks meibomian gland orifices. The targeted temperature needs to be approximately 40–42°C at the eyelid to effectively liquefy the meibum.

Eyelid massage – following warm compresses, gentle massage along the eyelid margin (using a clean finger, moving from inner to outer corner) expresses the softened meibum, clearing gland blockages and restoring lipid secretion.

Lid hygiene wipes or cleansers – hypoallergenic, preservative-free eyelid cleaning wipes remove the debris, biofilm, and demodex-associated matter that accumulates on eyelid margins and contributes to meibomian gland orifice obstruction. Daily use is recommended as a maintenance measure; preservative-free formulations prevent the additional ocular surface disruption that preserved products produce.

Consistent, daily warm compress and lid hygiene therapy requires patience – clinical studies show benefit emerging over 4–8 weeks of consistent practice. It is not a quick fix, but it is the only intervention that directly addresses the physical obstruction of meibomian gland orifices.

Step 3: Artificial Tears and Lubricating Drops

Artificial tears are the most universally available and most immediately effective symptomatic intervention for dry eye. Artificial tears provide symptomatic relief with limited impact on tear film stability. They play a role in symptom management and corneal epithelial wound healing; however, they only provide temporary relief.

Preservative-free formulations are essential for regular use. Benzalkonium chloride (BAK) – the most common preservative in eye drops – is toxic to corneal epithelial cells and meibomian gland cells with repeated exposure. Women using drops more than four times daily must use preservative-free formulations in single-dose vials or airless-pump multidose bottles. Using preserved drops multiple times daily is actively worsening the condition they are intended to treat.

Matching the drop to the mechanism:

• Aqueous-deficient dry eye: sodium hyaluronate (hyaluronic acid) drops are the evidence-supported first choice. Hyaluronic acid is a naturally occurring glycosaminoglycan with exceptional water-binding capacity, viscoelastic properties that closely mimic natural tears, and documented corneal epithelial protective effects. Concentrations of 0.1–0.4% are used; higher concentrations provide longer-lasting effect and are appropriate for more severe symptoms.
• Evaporative dry eye (meibomian gland dysfunction): lipid-containing drops that supplement the deficient lipid layer are more appropriate – these include liposomal sprays (applied to closed eyelids and spread by blinking), and lipid-containing tear formulations (containing mineral oil, castor oil, or lipid-based components). These are distinctly different from plain aqueous drops and are often overlooked in self-care.
• Mixed mechanism dry eye: combination formulations containing both aqueous and lipid components provide more comprehensive tear film supplementation.

Gel formulations and ointments – thicker viscosity products that provide longer-lasting lubrication. Gels are appropriate for daytime use in severe cases; ointments are appropriate for overnight use but cause blurring and should not be used during waking hours.

Step 4: Prescription Treatments

Cyclosporine eye drops – immunomodulatory treatment targeting the inflammatory cascade that underlies chronic dry eye disease. Available as Restasis (0.05%), CEQUA (0.09%), and VEVYE (0.1% – preservative-free). They work by suppressing T-lymphocyte-driven lacrimal gland inflammation, increasing functional tear production rather than simply replacing tears. They require 3–6 months for full effect and may cause temporary burning on instillation. They are appropriate for women with evidence of ocular surface inflammation or inadequate response to lubricating drops.

Lifitegrast (Xiidra) – a lymphocyte function-associated antigen 1 (LFA-1) integrin antagonist that specifically blocks the T-cell mediated inflammatory cycle at the ocular surface. Faster onset than cyclosporine (significant benefit at 2 weeks in some studies), with a similar duration to full effect.

Miebo (perfluorohexyloctane) – the most significant recent development in dry eye pharmacology. Miebo is the first FDA-approved prescription medication for dry eye associated with meibomian gland dysfunction. This preservative-free eyedrop is taken four times per day to stabilize tears and stave off evaporation. Patients have experienced a rapid decrease in dryness after using the drops. By acting as a semi-fluorinated alkane that forms a stable, evaporation-resistant film over the tear surface, it directly addresses the evaporative mechanism that drives menopausal dry eye at its source.

RP101 – Topical Estradiol Eye Drops (in clinical trial) – an actively evolving research area. Sex hormone receptors including estrogen receptors have been found to be present on the ocular surface in several tissues, such as the conjunctiva, cornea, and meibomian glands. The pronounced contrast in dry eye prevalence between men and women, especially postmenopausal women, points toward an involvement of sex hormones in the disease process. RP101, a therapeutic formulation containing 17-beta-estradiol as the active ingredient, is currently in randomized controlled trial for dry eye in postmenopausal women. This represents the most direct future pharmacological approach – treating the hormonal cause at the ocular surface level.

Punctal plugs – small silicone or collagen devices inserted into the tear ducts (puncta) to reduce tear drainage and extend the residence time of both natural and supplemental tears. Appropriate for women with documented aqueous deficiency whose tear volume is insufficient. Temporary dissolvable collagen plugs are often trialed first; if effective, permanent silicone plugs are placed.

In-office meibomian gland treatments:

• LipiFlow Thermal Pulsation – a device that applies vectored thermal pulsation to the eyelids, combining precisely regulated heat with gentle pressure to thoroughly clear meibomian gland blockages. A single 12-minute treatment produces improvements in meibomian gland function for 6–12 months.
• Intense Pulsed Light (IPL) – originally a dermatological laser treatment, now validated for meibomian gland dysfunction. IPL applied to the periocular skin improves meibomian gland function by reducing Demodex mite populations, decreasing telangiectatic blood vessel abnormalities that drive eyelid margin inflammation, and directly stimulating gland function. A series of 3–4 treatments 3–4 weeks apart produces significant improvement in meibomian gland function and dry eye symptoms.

Part 5: Omega-3 Fatty Acids – The Nuanced Evidence

Omega-3 supplementation is among the most widely recommended dietary interventions for dry eye disease. The clinical evidence is more nuanced than simple endorsement, and understanding the detail helps women make informed decisions.

What the 2025 Meta-Analysis Shows

A meta-analysis incorporating 19 related randomized controlled trials, encompassing 4,246 dry eye disease patients, found that omega-3 fatty acid supplementation showed benefit in tear break-up time, Schirmer’s test, osmolarity, and corneal fluorescein staining scores. However, given the heterogeneity in study results and diverse patient characteristics, caution is needed in generalizing these findings. Omega-3 fatty acid supplementation is still recommended for dry eye disease management in clinical settings.

The mechanism is anti-inflammatory: EPA and DHA from omega-3 sources reduce the production of pro-inflammatory prostaglandins and cytokines that drive ocular surface inflammation in chronic dry eye disease. They also have direct effects on meibomian gland lipid composition – improving the quality of meibum – and on lacrimal gland secretory function.

The DREAM Study Controversy

The 2018 Dry Eye Assessment and Management (DREAM) Study – the largest randomized controlled trial of omega-3 for dry eye, involving 535 patients – found no significant difference between high-dose omega-3 (3,000 mg EPA+DHA daily) and a refined olive oil placebo. This finding generated significant controversy. Subsequent analyses raised questions about whether olive oil was truly inert – it contains oleic acid (omega-9) which may have modest anti-inflammatory properties – and whether the patient population was appropriate for demonstrating omega-3 benefit. Smaller, more targeted studies continue to show positive effects in specific dry eye populations.

The Clinical Recommendation

The current evidence supports omega-3 supplementation as a reasonable, safe adjunct to other dry eye treatments, with the following practical guidance:

Dose: 2,000–3,000 mg EPA+DHA daily, taken with meals to improve absorption.

Form: Re-esterified triglyceride (rTG) forms have significantly superior bioavailability to ethyl ester (EE) forms – the majority of budget omega-3 supplements use ethyl ester form. Phospholipid-bound omega-3 (as found in krill oil) also shows superior bioavailability. Check the supplement label.

Duration: Allow 3–6 months for meaningful effect on tear film markers.

Dietary sources alongside supplementation: salmon, mackerel, sardines, herring (2–3 portions weekly), walnuts, chia seeds, and flaxseed oil all contribute EPA and DHA or their precursors.

Omega-7 (palmitoleic acid) – an emerging and promising fatty acid for dry eye specifically, found in sea buckthorn oil and in small quantities in macadamia nuts and avocado. Clinical studies show specific benefit for lacrimal gland secretory function. A randomized controlled trial published in Nutrients demonstrated restoration of tear secretion in a murine dry eye model with oral palmitoleic acid, and human data is emerging.

Part 6: Systemic Hormone Therapy and Dry Eye

The relationship between HRT and dry eye is the subject of active clinical investigation.

Systemic hormone replacement therapy has been both harmful and beneficial depending on the hormones and the patients.

The critical distinction – established by multiple observational studies – is between estrogen-only HRT (which is associated with worsened dry eye in most studies) and combined estrogen-plus-progesterone HRT (which is associated with neutral or modestly beneficial effects on dry eye). This aligns with the hormonal biology: estrogen alone may suppress meibomian gland lipid production; the progestogen component partially counteracts this.

The emerging research on topical estradiol eye drops (RP101) and topical androgen formulations applied to the eyelids represents the most direct future approach – delivering hormonal benefit to the ocular surface without systemic exposure.

For women already on systemic MHT, reporting significant dry eye symptoms to both their menopause specialist and eye specialist enables a coordinated approach: adjusting HRT formulation (adding or optimizing progesterone, considering transdermal rather than oral estrogen) alongside targeted ophthalmic management.

Part 7: The Practical Daily Protocol

Morning:

• Warm eye compress for 10 minutes during morning routine
• Gentle eyelid massage after compress
• Preservative-free lubricating drop on rising – before screens, before contact lenses
• Omega-3 supplement with breakfast

Through the day:

• Preservative-free drops as needed – no limit to frequency for preservative-free formulations; every 1–2 hours is appropriate during symptomatic periods
• 20-20-20 rule during screen use
• Hydration – adequate water intake (at least 2 liters daily)

Evening:

• Eyelid hygiene cleansing
• Lipid-containing drop or gel before bed
• For severe overnight dryness: preservative-free ointment on eyelid margins at bedtime

Review cosmetics: check paraben content of eye-area products; switch to mineral-based, paraben-free formulations where possible.

Attend regular eye examinations – at least annually. Mention menopausal status explicitly; ask for dry eye assessment specifically. An ophthalmologist or optometrist familiar with menopausal ocular changes can provide the integrated assessment that dry eye during this transition requires.

The Conclusion

Dry eye disease during perimenopause and menopause is a genuinely hormonal condition – mechanistically linked to androgen and estrogen changes at the level of the meibomian glands, lacrimal glands, and ocular surface – that affects a significant proportion of women during this transition. It is almost universally undertreated because the connection to menopause is not made, the range of treatment options is not communicated, and women accept worsening visual comfort as an inevitable consequence of ageing.

The treatment landscape is richer than most women are told. From daily warm compresses and preservative-free lipid-containing drops, to prescription cyclosporine, the new meibomian gland-specific Miebo formulation, in-office LipiFlow and IPL procedures, and the horizon of topical hormonal eye treatments – there is a genuinely effective stepped treatment pathway available. Omega-3 supplementation, at appropriate doses and quality, is a rational and evidence-informed adjunct.

Your eyes deserve the same hormonal awareness that the rest of your body is receiving. And they deserve a clinician who makes the connection.

For more useful articles and expert guidance, explore the Womeno app – your personal digital companion through the hormonal transition. Download the app HERE

Sources

1. Aggarwal S, Bhatt A. Dry Eye Syndrome in Menopause and Perimenopausal Age Group. Journal of Mid-life Health. 2017;8(2):51–54. PMID:28706404. doi:10.4103/jmh.JMH_41_17
2. Johns Hopkins Medicine. Perimenopause, Menopause and Dry Eyes. hopkinsmedicine.org. November 2025.
3. Optometrists.org. Dry Eye and Menopause. optometrists.org. July 2021.
4. Murthy R, Gallant Sullivan A, Sullivan DA. The Dry Eye Ménage-a-Trois: Sex, Hormones, and Cosmetics. The Ophthalmologist. July 2024. theophthalmologist.com (Citing: TFOS DEWS II Sex, Gender and Hormones Report)
5. Garhöfer G et al. Study targets dry eye disease in postmenopausal women. Ophthalmology Times. May 2026. (RP101 clinical trial)
6. Greenwich Eye / Greenwich Ophthalmology Associates. Menopause and Dry Eye Treatment Guide.greenwicheye.com. 2025.
7. Healthline. Menopause and Dry Eyes. healthline.com. Updated 2024.
8. Huang YC et al. Evaluation of the therapeutic effect of estrogen replacement therapy combined with autologous serum therapy in controlling severe dry eye disease in perimenopausal women. Scientific Reports. 2025. doi:10.1038/s41598-025-03638-9
9. Ahmad M et al. Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2023;12(20):7026. PMC10672334. doi:10.3390/jcm12207026
10. Paik B, Tong L. Topical Omega-3 Fatty Acids Eyedrops in the Treatment of Dry Eye and Ocular Surface Disease: A Systematic Review. International Journal of Molecular Sciences. 2022;23(21):13156. PMC9654205. doi:10.3390/ijms232113156
11. D’Angelo G et al. Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments. Pharmaceuticals (MDPI). 2025;18(7):994. PMC12298963. doi:10.3390/ph18070994
12. Chen W et al. Novel treatments for dry eye syndrome. Archivos de la Sociedad Española de Oftalmología (English Edition). 2024;99(6):237–247. doi:10.1016/j.oftale.2024.01.004
13. American Academy of Ophthalmology / Radcliffe N MD. Improved Dry Eye Drugs for 2025 and Beyond. aao.org. January 2025. (Citing: FDA approval Miebo; Lacrifill; VEVYE)
14. Cannon EyeCare. The Truth About Eye Drops: Which Ones Actually Help Dry Eyes. seattleeyecaredoctor.com. December 2025. (Citing: NOV03/Miebo Phase 3 trials, AAOJOURNAL)
15. Dove Medical Press / Bray J. Tolerability of current treatments for dry eye disease. Ophthalmology and Therapy. 2024. doi:10.2147/OPTH (Citing: TFOS DEWS II; omega-3 and omega-7 clinical evidence)
16. ClinicalTrials.gov NCT03097614. Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment. Treatment protocol document (artificial tears and punctal plugs evidence section)
17. Molina-Leyva I, Molina-Leyva A, Bueno-Cavanillas A. Efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids in dry eye syndrome: a systematic review of randomized clinical trials. Acta Ophthalmologica. 2017.
18. Ablamowicz AF, Nichols JJ, Nichols KK. Association between serum levels of testosterone and estradiol with meibomian gland assessments in postmenopausal women. Investigative Ophthalmology & Visual Science. 2016;57:295–300. PMC.
19. Steger B, Harrison RJ. Hormone replacement therapy and dry eye – a review. Contact Lens & Anterior Eye. 2024. (Combined vs. estrogen-only HRT and dry eye risk)
20. Kimura Y et al. Restoration of tear secretion in a murine dry eye model by oral administration of palmitoleic acid.Nutrients. 2017;9(4). doi:10.3390/nu9040364